The global malabsorption syndrome market size is expected to be worth USD 3.66 Billion in 2025. It can reach a valuation of USD 5.88 Billion by 2032. The market is anticipated to exhibit a CAGR of 7.00% during the forecast period (2025-2032).

The market growth is driven by the increasing number of patients affected by Crohn’s disease, short bowel syndrome, celiac disease, and chronic pancreatitis, and the recognition of doctors of the syndrome. Innovations in diagnostic tools to assess the presence of nutritional deficiencies and changes in diets can contribute to the market growth.

However, the lack of healthcare infrastructure in several countries and the drugs in the development phase can restrain the market growth.

Key Market Insights

The malabsorption syndrome market growth is driven by blood tests for accurate diagnosis, case studies and clinical trials for drug development, and personalized nutritional approaches for precise disease management.

• By product type, the lactose intolerance segment is expected to score a 21.0% share in 2025. This can be attributed to the healthcare spending in middle-income countries and the inability of various patients to process vital nutrients. Healthcare initiatives to create awareness by governments and drugs developed by pharmaceutical companies can drive the segment growth over the forecast period.
• By diagnosis, the endoscopy and biopsy segment is anticipated to attain a robust market share in 2025. The assessment of lactose intolerance for gastrointestinal cases is likely to drive the segment’s demand over the forecast period. The use of colonoscopy-based biopsy for differentiating between lactase deficiency causes can bode well for the segment.
• By treatment, the nutritional supplements segment is anticipated to attain a significant market share in 2025. The use of parenteral nutrition and enzyme supplements to overcome any deficiencies can drive the segment growth in the malabsorption syndrome market. This has led to the sale of probiotic enzyme formulas at retail pharmacy chains.
• By end user, the hospitals segment can account for a large market share in 2025 due to lactose intolerance-related cases being diagnosed at these institutions. The presence of multidisciplinary teams and nutrition management experts for the management of malabsorption can drive the segment.
• By region, Europe is anticipated to contribute greatly to the market revenue in 2025 owing to investments in research and development into the precise diagnosis of malabsorption syndrome and healthcare reimbursement schemes supported by governments in the region.

The full report is now available for purchase: https://www.coherentmi.com/industry-reports/malabsorption-syndrome-market

Malabsorption Syndrome Market Report Coverage

Market Dynamics

The rise of gluten intolerance cases due to Crohn’s disease, celiac disease, and others have driven the demand in the malabsorption syndrome market. A similar driver is a surge in lactose intolerance incidents that have led to bloating and discomfort.

The discovery of bacterial fermentation as a major cause of malabsorption of carbohydrates has driven the demand for alternative foods. Development of probiotic enzymes and enzymatic therapies are likely to shape the market demand in the coming years. The integration of Lactobacillus species in probiotics can aim to relieve patients of their symptoms.

Market Opportunity: Personalized Nutrition Using AI

Personalized nutrition approaches for the management of malabsorption syndrome can alleviate the patients of their discomfort. The development of AI platforms that link dietary intake and symptoms for the creatin of customized plans can augur favorably for the market. Suggestions of lactase doses and premium subscriptions can improve the health of patients. On March 26, 2025, FriskAi decided to release a free version of its personalized nutrition platform for individuals looking to change their lifestyle through AI recommendations.

Market Challenge: Regulatory Hurdles to Affect Market Growth

Stringent regulations for the safety of novel drugs and a lack of skilled personnel in the development of accurate tests can impede the market growth. According to 21 CFR § 314.126 outlined by the U.S. FDA, lack of efficacy displayed in clinical trials led to the approval of the drug. This was illustrated by the denial of Zealand Pharma’s glepaglutide. The drug failed to meet the substantial evidence requirement under U.S. FDA guidelines.

Malabsorption syndrome contains symptoms that overlap with other digestive disorders, making it difficult for clinicians to come up with an accurate diagnosis. However, the identification of tropical sprue as a definitive indicator of malabsorption syndrome can turn the tide in favor of growth for the market.

Analyst’s View

• The demand for lactase enzyme supplements and personalized nutrition approaches by doctors for the management of malabsorption syndrome can drive market growth.
• The nutritional supplements segment is expected to capture a large market share in 2025, owing to various nutritional deficiencies caused by malabsorption syndrome.
• Key players are mainly investing in improving the accuracy of blood tests and imaging techniques.

Recent Developments

Mayo Clinic Laboratories developed a blood test, serum 7α-hydroxy-4-cholesten-3-one (C4) test, for the accurate diagnosis of bile acid malabsorption on August 12, 2024. The combination of the blood test with a stool sample led to the creation of the malabsorption panel that aims to improve its diagnosis rate.

Competitor Insights

• Anthera Pharmaceuticals, Inc.
• Innovate Biopharmaceuticals
• Immunomedics, Inc.
• Biotest Pharmaceuticals Corporation
• Kedrion Biopharma Inc.
• Adma Biologics Inc.
• Novartis AG
• Biogen
• Amgen Inc.
• Takeda Pharmaceutical Company Limited
• Bayer AG
• Merck & Co., Inc.
• BioLineRx Ltd
• Bristol-Myers Squibb Company
• Celgene Corporation

Market Segmentation

• By Product Type
• Celiac Disease
• Lactose Intolerance
• Crohn’s Disease
• Tropical Sprue
• Short Bowel Syndrome
• By Diagnosis
• Blood Tests
• Endoscopy and Biopsy
• Imaging Tests
• Hydrogen Breath Test
• By Treatment
• Gluten-free Diet
• Anti-inflammatory Drugs
• Antibiotics
• Nutritional Supplements
• Protease and Lipase Supplements
• Antidiarrheal Agents
• Others
• By End User
• Hospitals
• Academic and Research Institutes
• Pharmaceutical Companies
• Nutrition Clinics
• Others

Regional Insights

• North America
  • U.S.
  • Canada
• Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
• Europe
  • Italy
  • Germany
  • U.K.
  • Spain
  • Russia
  • France
  • Rest of Europe
• Asia Pacific
  • South Korea
  • India
  • China
  • Japan
  • Australia
  • ASEAN
  • Rest of Asia Pacific
• Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
• Africa
  • South Africa
  • North Africa
  • Central Africa